Alnylam Pharmaceuticals | ALNY - Ebitda



Alnylam Pharmaceuticals reported $18.83M in EBITDA for its fiscal quarter ending in June of 2025.


Ebitda Change Date
Acadia Pharmaceuticals USD 35.31M 13.07M Jun/2025
Agios Pharmaceuticals USD -125797000 20.45M Jun/2025
Alnylam Pharmaceuticals USD 18.83M 13.65M Jun/2025
Amgen USD 3.6B 147M Jun/2025
Arrowhead Research USD -159327000 556.67M Jun/2025
BioMarin Pharmaceutical USD 295.45M 49.49M Jun/2025
Incyte USD 581.52M 358.87M Jun/2025
Ionis Pharmaceuticals USD 150.23M 291.7M Jun/2025
Moderna USD -760000000 164M Jun/2025
Neurocrine Biosciences USD 152.9M 121.6M Jun/2025
Novartis USD 6.08B 739M Jun/2025
PTC Therapeutics USD 971.14M 970.07M Mar/2025
Regeneron Pharmaceuticals USD 1.66B 926.5M Jun/2025
Sanofi EUR 1.89B 1.33B Jun/2025
Sarepta Therapeutics USD 126.42M 416.82M Jun/2025
Takeda JPY 366.2B 238.06B Jun/2025
Tectonic Therapeutic USD -13483000 5.73M Dec/2024
Ultragenyx Pharmaceutical USD -91344000 35.09M Jun/2025
Vertex Pharmaceuticals USD 1.34B 556.6M Jun/2025
Xencor USD -30519000 6.39M Jun/2025